Skip to main content
    D

    Dyne Therapeutics Inc (DYN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.29
    +0.25 (+1.66%)

    Market Cap: $2.81B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    38%(11/29)
    Avg Surprise
    -83.97%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.89
    Range$-1.09 - $-0.72
    14 analysts
    EPS Revisions
    1
    0
    7d
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.77-16.0%
    60d ago$-0.86-3.5%
    30d ago$-0.88-1.0%
    7d ago$-0.890.0%
    Current$-0.89
    Revenue Consensus
    $0
    Range$0 - $0
    15 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.13
    Range$-1.52 - $-0.52
    15 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    16 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.13---
    Sep 26EST
    		-$-0.89---
    Jun 26
    Reported Jul 27
    		$-1.08$-0.74-45.95%Miss-11.3%
    Mar 26
    Reported May 11
    		$-0.73$-0.78+6.41%Beat+30.5%
    Dec 25
    Reported Mar 2
    		$-0.73$-0.77+5.48%Beat+17.0%
    Sep 25
    Reported Nov 5
    		$-0.76$-0.81+6.17%Beat+20.8%
    Jun 25
    Reported Jul 28
    		$-0.97$-0.93-4.30%Miss-38.6%
    Mar 25
    Reported May 8
    		$-1.05$-0.84-25.00%Miss-29.6%
    Dec 24
    Reported Feb 27
    		$-0.88$-0.91+3.51%Beat+19.3%
    Sep 24
    Reported Nov 12
    		$-0.96$-0.71-35.21%Miss+3.0%
    Jun 24
    Reported Aug 12
    		$-0.70$-0.72+2.78%Beat+35.2%
    Mar 24
    Reported May 2
    		$-0.81$-0.80-1.25%Miss-3.8%
    Dec 23
    Reported Mar 5
    		$-1.09$-0.93-17.20%Miss-47.3%
    Sep 23
    Reported Oct 30
    		$-0.99$-0.76-30.26%Miss-23.7%
    Jun 23
    Reported Aug 3
    		$-1.08$-0.78-38.46%Miss-6.9%
    Mar 23
    Reported May 11
    		$-0.78$-0.76-2.63%Miss-13.0%
    Dec 22
    Reported Mar 2
    		$-0.74$-0.84+11.90%Beat+26.0%
    Sep 22
    Reported Nov 3
    		$-0.80$-0.92+13.04%Beat+3.6%
    Jun 22
    Reported Aug 4
    		$-1.01$-0.80-26.25%Miss-74.1%
    Mar 22
    Reported May 2
    		$-0.69$-0.88+21.59%Beat-38.0%
    Dec 21
    Reported Mar 10
    		$-1.00$-0.97-3.09%Miss-56.3%
    Sep 21
    Reported Nov 4
    		$-0.83$-0.66-25.76%Miss-167.7%
    Jun 21
    Reported Aug 5
    		$-0.58$-0.55-5.45%Miss-48.7%
    Mar 21
    Reported May 6
    		$-0.50$-0.62+19.35%Beat-42.9%
    Dec 20
    Reported Mar 4
    		$-0.64$-0.37-72.97%Miss-306.5%
    Sep 20
    Reported Nov 5
    		$-0.31$-0.39+20.51%Beat+72.3%
    Jun 20
    Reported Sep 17
    		$-0.39$0.00N/AMiss+68.5%
    Dec 17
    Reported Feb 22
    		$-0.35$-0.42+16.67%Beat+75.0%
    Sep 17
    Reported Nov 1
    		$0.31$0.55-43.64%Miss-
    Jun 17
    Reported Aug 4
    		$-1.12$-0.71-57.75%Miss-
    Mar 17
    Reported May 5
    		$-1.24$-0.11-1027.27%Miss-
    Dec 16
    Reported Feb 24
    		$-1.40$0.14-1100.00%Miss-

    Key Metrics

    Valuation
    P/E Ratio-4.63EV/EBITDAN/A
    Price/FCF-5.07xFCF Yield-19.73%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-81.60%ROIC-46.33%
    Financial Health
    Debt/Equity0.30xInterest Coverage-36.07x
    Current Ratio12.02xQuick Ratio12.02x
    Trading Statistics
    Beta1.12Avg Volume3.22M
    52-Week High$27.3052-Week Low$14.00

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$15.66
    SMA 20$16.06
    SMA 50$20.76
    SMA 200$19.43
    EMA 10$15.74
    EMA 20$16.60
    EMA 50$19.00
    EMA 200$19.26

    MACD

    Line: -1.35Signal: -1.57Hist: 0.22

    ADX

    ADX: 47.2+DI: 15.2-DI: 35.7

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down96.0
    PSAR$17.26

    Bollinger Bands

    Upper Band$17.36
    Lower Band$14.76
    %B Position1617%(Upper)
    Band Width0.20

    RSI (14-Day)

    Neutral
    32.1

    Momentum Oscillators

    Stoch %K16.9
    Stoch %D27.3
    Williams %R-77.7
    ROC (10d)-3.4%
    Momentum-0.53
    CCI (20d)-105.5
    MFI (14d)47.4

    Volatility Measures

    ATR (14d)$0.89(5.8%)
    StdDev (20d)0.65
    Hist Vol43.5%(High)

    Volume Flow

    VWAP$15.27
    OBV49.1M
    AD Line-2.3M
    CMF (20d)-0.089

    Volume Metrics

    Avg Vol (20d)3.3M
    Vol Ratio0.6x
    VWMA (20d)$16.10

    Pivot Points

    R3$16.11
    R2$15.76
    R1$15.40
    Pivot Point$15.05
    S1$14.70
    S2$14.35
    S3$13.99

    Advanced Oscillators

    TSI-41.95
    Ultimate Osc47.5
    KST-238.14

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$1.57M$0$0$0$3.79M$0
    Cost of Revenue$0$0$521,000$0$0$0N/A$0$0$0$567,000$0
    Gross Profit$0$0$-521,000$0$0$0$786,000$0$0$0$3.22M$0
    Operating Expenses$181.66M$125.28M$116.13M$113.89M$115.79M$122.37M$97.11M$105.66M$71.96M$69.16M$67.69M$62.27M
    R&D$152.17M$100.89M$95.43M$97.22M$99.24M$106.45M$81.80M$92.80M$62.26M$44.54M$58.84M$55.25M
    SG&A$29.49M$24.39M$20.70M$16.67M$16.55M$15.93M$15.30M$12.86M$9.70M$24.62M$8.84M$7.02M
    Operating Income$-181,661,000$-125,276,000$-116,129,000$-113,892,000$-115,791,000$-122,372,000$-97,198,000$-105,569,000$-71,962,000$-69,157,000$-67,689,000$-62,273,000
    Interest Income$7.79M$8.76M$7.66M$8.48M$6.63M$7.10M$7.59M$9.28M$7.05M$3.00M$1.75M$2.19M
    Interest Expense$4.59M$4.20M$0$2.90M$94,000$0$0$0$0$0$0$0
    Income Before Tax$-178,556,000$-120,854,000$-111,955,000$-108,041,000$-110,857,000$-115,361,000$-89,632,000$-97,035,000$-65,102,000$-65,649,000$-66,638,000$-60,210,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-178,556,000$-120,854,000$-111,955,000$-108,041,000$-110,857,000$-115,361,000$-89,542,000$-97,125,000$-65,102,000$-65,649,000$-66,638,000$-60,210,000
    EBITDA$-181,189,000$-124,859,000$-116,286,000$-113,458,000$-117,348,000$-122,575,000$-97,610,000$-106,849,000$-71,755,000$-68,265,000$-68,185,000$-62,333,000
    EBIT$-181,749,000$-125,409,000$-116,419,000$-113,613,000$-117,388,000$-122,461,000$-97,224,000$-106,311,000$-72,154,000$-68,651,000$-68,390,000$-62,399,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DYN

    News

    Can One Year DM1 Data Change The Bull Case For Dyne Therapeutics Stock?

    Dyne Therapeutics reported positive one-year data from its Phase 1/2 ACHIEVE trial for z basivarsen in DM1, showing sustained improvements and a favorable safety profile. This data supports the company's investment...

    Simply Wall Street•10/13/26•Somewhat-Bullish

    Can One Year DM1 Data Change The Bull Case For Dyne Therapeutics Stock?

    Dyne Therapeutics has released positive one-year data from its Phase 1/2 ACHIEVE trial for z basivarsen in DM1, showing sustained improvements. This supports the company's investment thesis...

    Simply Wall Street•10/13/26•Somewhat-Bullish

    How (DYN) Movements Inform Risk Allocation Models

    This article analyzes Dyne Therapeutics Inc. (NYSE: DYN) movements, noting positive near-term sentiment amidst a weak mid-term and strong long-term context. It highlights elevated downside risk and provides AI-generated...

    Stock Traders Daily•10/11/26•Somewhat-Bullish

    Dyne Therapeutics (DYN) After Fresh ACHIEVE Data With Undervalued Narrative Intact

    Dyne Therapeutics (DYN) has released new one-year results from its Phase 1/2 ACHIEVE trial for DYNE-101 in myotonic dystrophy type 1, showing sustained functional gains. Despite a recent share price decline...

    Simply Wall Street•10/7/26•Somewhat-Bullish

    Does One Year DM1 Trial Data Change The Bull Case For Dyne Therapeutics Stock?

    Dyne Therapeutics released positive one-year data from its Phase 1/2 ACHIEVE trial for zeleciment basivarsen in DM1...

    Simply Wall Street•10/6/26•Somewhat-Bullish

    DYN Valuation and Fair Value

    P/E
    -4.6x
    P/FCF
    -5.1x
    PEG
    0.2x
    P/B
    3.6x
    See GNG's fair value

    DYN Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -46.3%
    ROE
    -81.6%
    FCF yield
    -19.7%

    DYN Competitors

    CompanyTicker
    Soleno Therapeutics IncSLNO
    Privia Health Group IncPRVA
    Arcus Biosciences IncRCUS
    Aveanna Healthcare Holdings IncAVAH
    Denali Therapeutics IncDNLI
    Neogen CorporationNEOG
    Enliven Therapeutics Inc.ELVN
    Precigen IncPGEN

    Sector: Healthcare

    DYN Analyst Ratings

    Consensus
    Buy
    Analysts
    17
    Strong Buy
    3
    Buy
    13
    Hold
    0
    Sell
    0
    Strong Sell
    1

    DYN Bull Case vs Bear Case

    Bull case

    • 94.1% of DYN's analyst ratings are Buy or Strong Buy.

    DYN Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -11.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.89
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 1 down

    Frequently Asked Questions About DYN

    Does DYN pay dividends?

    Dyne Therapeutics Inc (DYN) does not currently pay a regular dividend.

    What is DYN's market cap?

    Dyne Therapeutics Inc (DYN) has a market capitalization of $2.81B with a current stock price of $15.29.

    Related stocks

    Sector: Healthcare

    All stocks starting with D

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In